{'fraction_non_alphanumeric': 0.03489640130861505, 'fraction_numerical': 0.017993456924754635, 'mean_word_length': 5.416083916083916, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice

The hemoregulatory peptide, pGlu‐Glu‐Asp‐Cys‐Lys (pEEDCK or HP5b), has been shown to reversibly inhibit the proliferation of bone‐marrow progenitor cells, and has been reported to protect mice from the myelotoxicity associated with ara‐C, a chemotherapeutic agent. We undertook to use this reagent to reduce radioimmunotherapy(RAIT)‐associated bone‐marrow toxicity by suppressing hematopoiesis during the critical period when bone marrow is exposed to radiation. The reported studies optimize the use of HP5b to reduce the duration of neutropenia and thrombocytopenia. We found that 3.6 μg/day of HP5b administered through a continuous 7d mini‐osmotic pump, together with a bolus dose of 3.6 μg 3 hours before the radioantibody dose, gave the best effect, as measured by neutrophil counts on day 28 post RAIT. With sub‐lethal doses of RAIT, the period of neutropenia was reduced by 2 weeks, and there appeared to be more rapid recovery of morphologically mature myeloid cells. The peptide, however, does not appear to alleviate the lymphotoxicity associated with RAIT. No adverse effects have been noted from continuous infusions of the peptide. In the past, we reported that cytokines (IL‐1/GM‐CSF) are not marrow‐restorative when given after RAIT. However, an additive effect is observed when HP5b infusions are combined with post‐RAIT cytokine administration, suggesting that a significant pool of bone‐marrow progeniter cells remains when HP5b is co‐administered with RAIT. Thus, HP5b is an alternate approach to reducing myelotoxicity, and may be used in combination with cytokines to further reduce the duration of myelosuppression. Int. J. Cancer, 70:323–329, 1997. © 1997 Wiley‐Liss, Inc.